Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for transplantation, autoimmune diseases, and neurodegenerative conditions. The company's lead investigational product is tegoprubart, a humanized anti-CD40L antibody that targets the CD40 ligand pathway, a well-validated biological mechanism for immune regulation. Tegoprubart is being evaluated across multiple therapeutic areas, including kidney allograft transplantation through the Phase 2 BESTOW trial, islet cell transplantation for type 1 diabetes management, and xenotransplantation procedures. The company is also exploring applications in amyotrophic lateral sclerosis treatment. Eledon's clinical development strategy encompasses Phase 2 studies demonstrating promising kidney function outcomes and favorable safety profiles compared to standard immunosuppressive regimens. The company is advancing toward Phase 3 clinical trials and regulatory discussions with the FDA. Eledon maintains active collaborations with leading transplant centers and research institutions to expand its therapeutic potential across multiple indication areas.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. David-Alexandre C. Gros M.D., Ph.D.

Employees

31

Headquarters

Irvine, CA, United States

Website

eledon.com